Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Volume: 4, Issue: 2, Pages: 156 - 164
Published: Jan 22, 2015
Abstract
Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes were recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC) lacking activating EGFR, KRAS, ALK, BRAF, or HER2 oncogene aberrations. RET and ROS1 fusion-positive tumors are mainly observed in young, female, and/or never smoking patients. Studies based on in vitro and in vivo (i.e., mouse) models and studies of...
Paper Details
Title
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Published Date
Jan 22, 2015
Volume
4
Issue
2
Pages
156 - 164
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.